Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945721 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
A Phase 1 study of Triple Negative Breast Cancer and Residual Disease, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT03945721: Active Phase 1 study of Triple Negative Breast Cancer and Residual Disease, sponsored by Massachusetts General Hospital.
NCT03945721 is a Phase 1 study of Triple Negative Breast Cancer and Residual Disease that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 21 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03945721, a Phase 1 study of Triple Negative Breast Cancer and Residual Disease, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
Primary Outcome
The proportion of subjects tolerating each maximum dose level. The trial will be monitored using a 3+3 dose escalation method.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Niraparib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana Farber Cancer Institute/Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What the registry record for NCT03945721 still lists
NCT03945721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT03945721 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03945721 about?
NCT03945721 is a clinical study titled "A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients". This research study involves Niraparib as a possible treatment for triple negative breast cancer.
What is the current status of trial NCT03945721?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2019-07-11. Estimated completion is 2028-12-31.
What conditions does trial NCT03945721 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, Residual Disease.
What interventions are being tested in trial NCT03945721?
The interventions under investigation include: Radiation Therapy (RADIATION), Niraparib (DRUG).
Who is sponsoring clinical trial NCT03945721?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945721 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03945721's enrollment target sits among peer trials
21 102nd of 118 higher than 17 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI